NCT06840899 CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
| NCT ID | NCT06840899 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Wisconsin, Madison |
| Condition | Supra-sacral Spinal Cord Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-02-13 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 20 participants in total. It began in 2026-02-13 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days
Eligibility Criteria
Inclusion Criteria: * \>18 years of age * History of supra-sacral spinal cord injury of any mechanism * Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock) * Willingness to participate in drug intervention trial * English-speaking (able to provide consent and complete questionnaires) Exclusion Criteria: * History of intravesical Botox * Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms * Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported * Thought or mood disorder aside from depression
Contact & Investigator
Javi Santiago
PRINCIPAL INVESTIGATOR
University of Wisconsin, Madison
Frequently Asked Questions
Who can join the NCT06840899 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Supra-sacral Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06840899 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06840899 currently recruiting?
Yes, NCT06840899 is actively recruiting participants. Contact the research team at flory@ortho.wisc.edu for enrollment information.
Where is the NCT06840899 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT06840899 clinical trial?
NCT06840899 is sponsored by University of Wisconsin, Madison. The principal investigator is Javi Santiago at University of Wisconsin, Madison. The trial plans to enroll 20 participants.